- Home
- PLX vs SKYE Comparison
PLX vs SKYE Comparison
Compare PLX & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLX
- SKYE
- Stock Information
- Founded
- PLX 1993
- SKYE 2012
- Country
- PLX Israel
- SKYE United States
- Employees
- PLX N/A
- SKYE N/A
- Industry
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- PLX Health Care
- SKYE Health Care
- Exchange
- PLX Nasdaq
- SKYE Nasdaq
- Market Cap
- PLX 132.5M
- SKYE 108.3M
- IPO Year
- PLX 1998
- SKYE N/A
- Fundamental
- Price
- PLX $1.76
- SKYE $2.70
- Analyst Decision
- PLX
- SKYE Buy
- Analyst Count
- PLX 0
- SKYE 6
- Target Price
- PLX N/A
- SKYE $18.67
- AVG Volume (30 Days)
- PLX 382.4K
- SKYE 193.9K
- Earning Date
- PLX 11-14-2024
- SKYE 02-09-2025
- Dividend Yield
- PLX N/A
- SKYE N/A
- EPS Growth
- PLX N/A
- SKYE N/A
- EPS
- PLX N/A
- SKYE N/A
- Revenue
- PLX $45,667,000.00
- SKYE N/A
- Revenue This Year
- PLX N/A
- SKYE N/A
- Revenue Next Year
- PLX $88.94
- SKYE N/A
- P/E Ratio
- PLX N/A
- SKYE N/A
- Revenue Growth
- PLX N/A
- SKYE N/A
- 52 Week Low
- PLX $0.82
- SKYE $2.25
- 52 Week High
- PLX $1.90
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- PLX 62.98
- SKYE 25.41
- Support Level
- PLX $1.60
- SKYE $3.21
- Resistance Level
- PLX $1.83
- SKYE $3.55
- Average True Range (ATR)
- PLX 0.08
- SKYE 0.40
- MACD
- PLX -0.02
- SKYE -0.08
- Stochastic Oscillator
- PLX 71.15
- SKYE 1.93
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.